TA

Thomas R. Alessi

IT Intarcia Therapeutics: 18 patents #4 of 56Top 8%
AP Amerimas Home Products: 9 patents #85 of 715Top 15%
DL Discovery Laboratories: 1 patents #7 of 20Top 35%
IT I2O Therapeutics: 1 patents #7 of 11Top 65%
📍 Hayward, CA: #41 of 1,120 inventorsTop 4%
🗺 California: #17,896 of 386,348 inventorsTop 5%
Overall (All Time): #129,549 of 4,157,543Top 4%
29
Patents All Time

Issued Patents All Time

Showing 1–25 of 29 patents

Patent #TitleCo-InventorsDate
12042557 Rapid establishment and/or termination of substantial steady-state drug delivery Kenneth L. Luskey 2024-07-23
11246913 Suspension formulation comprising an insulinotropic peptide Ryan D. Mercer, Catherine M. Rohloff, Bing Yang 2022-02-15
10869830 Rapid establishment and/or termination of substantial steady-state drug delivery Kenneth L. Luskey 2020-12-22
10583080 Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c Michelle Baron 2020-03-10
10527170 Osmotic delivery systems and piston assemblies for use therein Michael A. Desjardin, Stan Lam, Scott D. Lautenbach, Pauline C. Zamora 2020-01-07
10441528 Devices, formulations, and methods for delivery of multiple beneficial agents Karling Alice Leung, Ryan D. Mercer, Cristina G. Negulescu, Catherine M. Rohloff, Bing Yang 2019-10-15
10363287 Method of manufacturing an osmotic delivery device Ryan D. Mercer, Catherine M. Rohloff, Bing Yang 2019-07-30
10231923 Rapid establishment and/or termination of substantial steady-state drug delivery Kenneth L. Luskey 2019-03-19
9889085 Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c Michelle Baron 2018-02-13
9682127 Osmotic delivery device comprising an insulinotropic peptide and uses thereof Ryan D. Mercer, Catherine M. Rohloff, Bing Yang 2017-06-20
9572889 Devices, formulations, and methods for delivery of multiple beneficial agents Karling Alice Leung, Ryan D. Mercer, Cristina G. Negulescu, Catherine M. Rohloff, Bing Yang 2017-02-21
8940316 Osmotic delivery comprising an insulinotropic peptide and uses thereof Ryan D. Mercer, Catherine M. Rohloff, Bing Yang 2015-01-27
8926595 Devices, formulations, and methods for delivery of multiple beneficial agents Karling Alice Leung, Ryan D. Mercer, Cristina G. Negulescu, Catherine M. Rohloff, Bing Yang 2015-01-06
8801700 Osmotic delivery systems and piston assemblies for use therein Michael A. Desjardin, Stan Lam, Scott D. Lautenbach, Pauline C. Zamora 2014-08-12
8343140 Devices, formulations, and methods for delivery of multiple beneficial agents Karling Alice Leung, Ryan D. Mercer, Cristina G. Negulescu, Catherine M. Rohloff, Bing Yang 2013-01-01
8298561 Rapid establishment and/or termination of substantial steady-state drug delivery Kenneth L. Luskey 2012-10-30
8299025 Suspension formulations of insulinotropic peptides and uses thereof Ryan D. Mercer, Catherine M. Rohloff, Bing Yang 2012-10-30
7879028 Osmotic delivery systems and piston assemblies for use therein Michael A. Desjardin, Stan Lam, Scott D. Lautenbach, Pauline C. Zamora 2011-02-01
7682356 Osmotic delivery systems and piston assemblies for use therein Michael A. Desjardin, Stan Lam, Scott D. Lautenbach, Pauline C. Zamora 2010-03-23
5962523 Methods of using butyric acid derivatives to protect against hair loss S. Moran 1999-10-05
4966975 Processes for the preparation of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents John W. Ellingboe, Jehan F. Bagli 1990-10-30
4906753 Preparation of 2,6-disubstituted-5-cyano-4-pyrimidinyloxyacetic acid aldose reductase inhibitors Jehan F. Bagli, John W. Ellingboe 1990-03-06
4900829 2,4-disubstituted-5-cyano-1,6-dihydro-6-oxo-1-pyrimidineacetic acid aldose reductase inhibitors Jehan F. Bagli, John W. Ellingboe 1990-02-13
4897405 Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents Terence M. Dolak, John W. Ellingboe, Louis J. Lombardo 1990-01-30
4895860 Novel substituted 3H-1,2,3,5-oxathiadiazole 2-oxides useful as anthihyperglycemic agents John W. Ellingboe 1990-01-23